TDZD-8 pre-treatment in transient middle cerebral artery occlusion

Biomedicine and Aging Pathology

Volumn 4, Issue 4, 2014, Pages 361-367

  Ratilal, Bernardo Oliveira ^a   Rocha, João Pedro Fidalgo ^b   Fernandes, Adelaide Maria Afonso ^b   Arroja, Mariana Moreira Coutinho ^b   Barateiro, Andreia Pereira ^b   Brites, Dora Maria Tuna Oliveira ^b   Pinto, Rui Manuel Amaro ^b   Sepodes, Bruno Miguel Nogueira ^b   Mota Filipe, Helder Dias ^b  

^a HOSPITAL DE SÃO JOSÉ   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

GSK 3 inhibitor; Intracranial aneurysm surgery; Ischemia reperfusion; Neuroprotection; Transient focal cerebral ischemia

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; NEURON SPECIFIC ENOLASE; NEUROPROTECTIVE AGENT; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION SIZE; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IPSILATERAL HEMISPHERIC EDEMA; LASER DOPPLER FLOWMETRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGIC DISEASE; NEUROLOGICAL DEFICIT; NONHUMAN; RAT; WESTERN BLOTTING;

EID: 84908333539     PISSN: 22105220     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomag.2014.07.005     Document Type: Article

References (35)

1. Lavine SD, Masri LS, Levy ML, Giannotta SL. Temporary occlusion of the middle cerebral artery in intracranial aneurysm surgery: time limitation and advantage of brain protection. J Neurosurg 1997;87:817-24.
2. Ha SK, Lim DJ, Seok BG, Kim SH, Park JY, Chung YG. Riskof stroke with temporary arterial occlusion in patients undergoing craniotomy for cerebral aneurysm. J Korean Neurosurg Soc 2009;46:31-7.
3. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, owells HDW. 1026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77.
4. Hindman BJ, Bayman EO, Pfisterer WK, Torner JC, Todd MM, IHAST Investigators. No association between intraoperative hypothermia or supplemental protective drug and neurologic outcomes in patients undergoing temporary clipping during cerebral aneurysm surgery: findings from the Intraoperative Hypothermia for Aneurysm Surgery Trial. Anesthesiology 2010;112:86-101.
5. Li LR, You C, Chaudhary B. Intraoperative mild hypothermia for postoperative neurological deficits in intracranial aneurysm patients. Cochrane Database Syst Rev 2012, http://dx.doi.org/10.1002/14651858.CD008445.pub2.
6. Zhao ZX, Wu C, He M. A systematic review of clinical outcomes, perioperative data and selective adverse events related to mild hypothermia in intracranial aneurysm surgery. Clin Neurol Neurosurg 2012;114:827-32.
7. Dugo L, Collin M, Thiemermann C. Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock 2007;27:113-23.
8. Lei P, Ayton S, Bush AI, Adlard PA. GSK-3 in neurodegenerative diseases. Int J Alzheimers Dis 2011;2011:189246.
9. Ren M, Senatorov VV, Chen RW, Chuang DM. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A 2003;100:6210-5.
10. Sasaki C, Hayashi T, Zhang WR, Warita H, Manabe Y, Sakai K, et al. Different expression of glycogen synthase kinase-3beta between young and old rat brains after transient middle cerebral artery occlusion. Neurol Res 2001;23: 588-92.
11. Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 beta(GSK-3beta) inhibitors: thiadiazolidinones (TDZD)as potential drugs forthe treatment of Alzheimer's disease. J Med Chem 2002;45:1292-9.
12. Saitoh M, Kunitomo J, Kimura E, Iwashita H, Uno Y, Onishi T, et al. 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability. J Med Chem 2009;52:6270-86.
13. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002;22:373-84.
14. Collino M, Thiemermann C, Mastrocola R, Gallicchio M, Benetti E, Miglio G, et al. Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock 2008;30:299-307.
15. Cuzzocrea S, Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muià C, et al. Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther 2006;318:79-89.
16. Cuzzocrea S, Mazzon E, Di Paola R, Muià C, Crisafulli C, Dugo L, et al. Glycogen synthase kinase-3bet inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol 2006;120:57-67.
17. Bao H, Ge Y, Zhuang S, Dworkin LD, Liu Z, Gong R. Inhibition of glycogen synthase kinase-3β prevents NSAID-induced acute kidney injury. Kidney Int 2012;81:662-73.
18. Whittle BJ, Varga C, Posa A, Molnar A, Collin M, Thiemermann C. Reduction of experimental colitis in the rat byinhibitors ofglycogen synthase kinase-3beta. Br J Pharmacol 2006;147:575-82.
19. www.clinicaltrials.gov [cited 2014 April 4]. Available from http://www.clinicaltrials.gov/ct2/show/NCT01049399?term=NP031112&rank=1
20. Del Ser T, Steinwachs KC, Gertz HJ, Andrés MV, Gómez-Carrillo B, Medina M, et al. Treatment of Alzheimers disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis 2013;33:205-15.
21. Aguilar-Morante D, Morales-Garcia JA, Sanz-San Cristobal M, Garcia-Cabezas MA, Santos A, Perez-Castillo A. Inhibition ofglioblastoma growth by the thia-diazolidinone compound TDZD-8. PLoS One 2010;5:e13879.
22. Ratilal BO, Arroja MM, Rocha JP, Fernandes AM, Barateiro AP, Brites DM, et al. Neuroprotective effects of erythropoietin pretreatment in a rodent model of transient middle cerebral artery occlusion. J Neurosurg 2014;121:55-62.
23. Justicia C, Martín A, Rojas S, Gironella M, Cervera A, Panés J, et al. Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice. J Cereb Blood Flow Metab 2006;26:421-32.
24. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. Asemi-automated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990;10:290-3.
25. Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc 2008, http://dx.doi.org/10.1101/pdb.prot4986.
26. Ahmad O, Wardlaw J, Whiteley WN. Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review. Cerebrovasc Dis 2012;33:47-54.
27. Ramirez SH, Fan S, Zhang M, Papugani A, Reichenbach N, Dykstra H, et al. Inhibition of glycogen synthase kinase 3beta (GSK3beta) decreases inflammatory responses in brain endothelial cells. Am J Pathol 2010;176:881-92.
28. Zhou X, Zhou J, Li X, Guo C, Fang T, Chen Z. GSK-3β inhibitors suppressed neu-roinflammation in rat cortex by activating autophagy in ischemic brain injury. Biochem Biophys Res Commun 2011;411:271-5.
29. Beurel E, Jope RS. Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes. Neuroscience 2010;169:1063-70.
30. Ramirez SH, Fan S, Dykstr H, Rom S, Mercer A, Reichenbach NL, et al. Inhibition of glycogen synthas kinase 3 promotes tight junction stability in brain endothelial cells by half-life extension of occludin and claudin-5. PLoS One 2013;8:e55972.
31. Zhao H, Sapolsky RM, Steinberg GK. Phosphoinositide-3-kinase/akt survival signal pathways are implicated in neuronal survival afterstroke. Mol Neurobiol 2006;34:249-70.
32. Xuan Nguyen TL, Choi JW, Lee SB, Ye K, Woo SD, Lee KH, et al. Akt phospho-rylation is essential for nuclear translocation and retention in NGF-stimulated PC12 cells. Biochem Biophys Res Commun 2006;349:789-98.
33. Masuyama N, Oishi K, Mori Y, Ueno T, Takahama Y, Gotoh Y. Akt inhibits the orphan nuclear receptor Nur77 and T-cell apoptosis. J Biol Chem 2001;276:32799-805.
34. Lan R, Xiang J, Zhang Y, Wang GH, Bao J, Li WW, et al. PI3K/Akt pathway contributes to neurovascular unit protection of Xiao-Xu-Ming decoction against focal cerebral ischemia and reperfusion injury in rats. Evid Based Complement Alternat Med 2013:459467.
35. Xie R, Cheng M, Li M, Xiong X, Daadi M, Sapolsky RM, et al. Akt isoforms differentially protect against stroke-induced neuronal injury by regulating mTOR activities. J Cereb Blood Flow Metab 2013;33:1875-85.